Mapk/erk signaling pathway in hepatocellular carcinoma

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. Recently, the MAPK/ERK signaling pathway in HCC has gained renewed attention from basic and clinical researchers. The MAPK/ERK signaling pathway is activated in more than 50% of human HCC cases; however, activating mutations in RAS and RAF genes are rarely found in HCC, which are major genetic events leading to the activation of the MAPK/ERK signaling pathway in other cancers. This suggests that there is an alternative mechanism behind the activation of the signaling pathway in HCC. Here, we will review recent advances in understanding the cellular and molecular mechanisms involved in the activation of the MAPK/ERK signaling pathway and discuss potential therapeutic strategies targeting the signaling pathway in the context of HCC.

Original languageEnglish
Article number3026
Issue number12
Publication statusPublished - 2 Jun 2021


  • Animal models
  • Hepatocellular carcinoma
  • MAPK/ERK signaling
  • Targeted therapies


Dive into the research topics of 'Mapk/erk signaling pathway in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this